MEDTIDE (03880) surged over 9% in morning trading, reaching a high of HK$40.54 and setting a new record since its listing. As of press time, the stock was up 8.9% to HK$40.14, with turnover of HK$21.0322 million.
On the news front, MEDTIDE will convene a board meeting on August 29 to approve its interim results. According to Frost & Sullivan data, MEDTIDE ranked as the world's third-largest peptide-focused CRDMO by revenue in 2023, capturing a 1.5% market share. The company provides comprehensive services spanning the entire lifecycle from early discovery, preclinical research, and clinical development to commercial manufacturing.
The top two players in the global peptide-focused CRDMO market hold a combined 23.8% market share, while the remaining participants are relatively fragmented. The third to sixth largest participants (including MEDTIDE) each held approximately 1% market share in 2023.
According to prospectus data, MEDTIDE's revenue in recent years reached RMB 351 million, RMB 337 million, and RMB 442 million respectively, demonstrating strong momentum. This growth is supported by a diversified customer base and global footprint, with corporate clients spanning over 50 countries worldwide. Revenue distribution shows the United States accounting for 55%, mainland China 21.4%, Japan 7.1%, and Europe 11%. This geographically dispersed market presence effectively hedges against risks associated with dependence on a single market.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。